MCID: ADN018
MIFTS: 59

Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenoma

MalaCards integrated aliases for Adenoma:

Name: Adenoma 12 74 54 15 71
Acinar Cell Adenoma 12 71
Adenomas 12 15
Acinic Cell Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:657
MeSH 43 D000236
NCIt 49 C2855 C4196
SNOMED-CT 67 32048006 79041005
UMLS 71 C0001430 C0334389

Summaries for Adenoma

Disease Ontology : 12 A cell type benign neoplasm that is composed of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary : Adenoma, also known as acinar cell adenoma, is related to familial isolated pituitary adenoma and parathyroid adenoma. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Signaling by GPCR and Toll-like Receptor Signaling Pathway. The drugs Linaclotide and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and colon, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 An adenoma is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or... more...

Related Diseases for Adenoma

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1753)
# Related Disease Score Top Affiliating Genes
1 familial isolated pituitary adenoma 35.0 MEN1 AIP
2 parathyroid adenoma 34.8 RET MEN1 GNAS CTNNB1 CDC73 CCND1
3 pituitary adenoma, prolactin-secreting 34.8 MEN1 GNAS AIP
4 colorectal adenoma 34.8 MSH2 MLH1 KRAS CTNNB1 CCND1 APC
5 villous adenoma 34.8 MLH1 KRAS GNAS BRAF APC
6 pleomorphic adenoma 34.7 PLAGL2 PLAG1 CTNNB1
7 growth hormone secreting pituitary adenoma 34.6 MEN1 GNAS AIP
8 functioning pituitary adenoma 34.5 MEN1 GNAS AIP
9 apocrine adenoma 34.5 PLAG1 KRAS BRAF
10 follicular adenoma 34.5 TSHR RET MEN1 GNAS BRAF
11 extrahepatic bile duct adenoma 34.4 MSH2 MLH1
12 silent pituitary adenoma 34.3 MEN1 AIP
13 periampullary adenoma 34.3 KRAS APC
14 colon adenoma 34.2 SMAD4 KRAS APC
15 polyposis syndrome, hereditary mixed, 1 34.1 MSH2 MLH1 APC
16 null pituitary adenoma 34.1 MEN1 AIP
17 hyperparathyroidism 2 with jaw tumors 34.0 RET MEN1 CDC73 CCND1
18 hyperparathyroidism 1 33.9 MEN1 CDC73
19 carney complex variant 33.6 RET MEN1 GNAS CTNNB1 AIP
20 mismatch repair cancer syndrome 33.4 MSH2 MLH1 CTNNB1 APC
21 multiple endocrine neoplasia, type i 33.4 RET MEN1 GNAS CDC73 AIP
22 primary hyperparathyroidism 33.4 RET MEN1 CDC73 CCND1
23 parathyroid carcinoma 33.3 RET MEN1 CDC73 CCND1 APC
24 familial adenomatous polyposis 33.3 SMAD4 MSH2 MLH1 KRAS CTNNB1 CCND1
25 precocious puberty, male-limited 33.3 TSHR LHCGR GNAS
26 endometrial adenocarcinoma 33.2 MLH1 KRAS CTNNB1 CCND1
27 myh-associated polyposis 33.1 MSH2 KRAS APC
28 primary pigmented nodular adrenocortical disease 33.1 MEN1 GNAS CTNNB1
29 juvenile polyposis syndrome 33.0 SMAD4 MSH2 MLH1 APC
30 multiple endocrine neoplasia, type iia 33.0 RET MEN1 CDC73
31 appendix adenocarcinoma 33.0 KRAS GNAS
32 adrenal carcinoma 33.0 MEN1 CTNNB1 CCND1
33 hyperpituitarism 32.9 MEN1 GNAS AIP
34 pituitary tumors 32.6 MEN1 GNAS AIP
35 gastric cancer 32.6 TGFBR2 SMAD4 MSH2 MLH1 KRAS CTNNB1
36 thyroid carcinoma 32.1 TSHR RET BRAF
37 goiter 32.0 TSHR RET GNAS
38 adenocarcinoma 31.9 TGFBR2 SMAD4 RET MSH2 MLH1 KRAS
39 papillary carcinoma 31.8 TSHR RET GNAS BRAF
40 pituitary carcinoma 31.6 MEN1 GNAS AIP
41 hormone producing pituitary cancer 31.6 MEN1 GNAS AIP
42 meningioma, familial 31.5 RET MEN1 CTNNB1 CCND1
43 thyroiditis 31.5 TSHR RET BRAF
44 rectum cancer 31.5 MSH2 MLH1 KRAS APC
45 multinodular goiter 31.5 TSHR RET GNAS
46 colorectal adenocarcinoma 31.4 MSH2 MLH1 KRAS CTNNB1 CCND1 BRAF
47 hemangioma 31.4 RET MEN1 KRAS CTNNB1
48 nodular goiter 31.4 TSHR RET BRAF
49 ulcerative colitis 31.4 SMAD4 MSH2 MLH1 CTNNB1
50 adrenocortical carcinoma, hereditary 31.4 GNAS CTNNB1 BRAF

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma

Symptoms & Phenotypes for Adenoma

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 100)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.67 MLH1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.67 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.67 SMAD4 TGFBR2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.67 PLAGL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-111 10.67 MEN1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.67 TGFBR2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.67 SLC26A3 KRAS
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.67 MLH1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.67 PLAGL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.67 MEN1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.67 RET
12 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.67 TGFBR2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.67 APC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-134 10.67 CCND1 SLC26A3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-141 10.67 PLAGL2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.67 TGFBR2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.67 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.67 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.67 MEN1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.67 TGFBR2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-165 10.67 TGFBR2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.67 RET
23 Increased shRNA abundance (Z-score > 2) GR00366-A-18 10.67 PLAG1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.67 TGFBR2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-188 10.67 TGFBR2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.67 APC
27 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.67 MLH1 SMAD4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.67 MLH1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.67 APC
30 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.67 PLAG1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.67 CCND1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.67 CCND1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.67 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-212 10.67 SMAD4
35 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.67 RET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.67 KRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.67 SMAD4
38 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.67 RET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.67 CCND1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.67 TGFBR2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.67 SMAD4
42 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.67 CTNNB1 MEN1 BRAF
43 Increased shRNA abundance (Z-score > 2) GR00366-A-48 10.67 TGFBR2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.67 PLAG1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.67 RET
46 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.67 SLC26A3
47 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.67 RET TGFBR2
48 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.67 KRAS
49 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.67 TGFBR2
50 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.67 RET

MGI Mouse Phenotypes related to Adenoma:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 AIP APC BRAF CCND1 CDC73 CTNNB1
2 endocrine/exocrine gland MP:0005379 10.52 AIP APC BRAF CCND1 CDC73 CTNNB1
3 growth/size/body region MP:0005378 10.51 AIP APC BRAF CCND1 CDC73 CTNNB1
4 homeostasis/metabolism MP:0005376 10.51 AIP APC BRAF CCND1 CDC73 CTNNB1
5 digestive/alimentary MP:0005381 10.48 APC BRAF CCND1 CDC73 CTNNB1 KRAS
6 behavior/neurological MP:0005386 10.47 APC BRAF CCND1 CDC73 CTNNB1 GNAS
7 cardiovascular system MP:0005385 10.44 AIP APC BRAF CCND1 CDC73 CTNNB1
8 hematopoietic system MP:0005397 10.44 APC BRAF CCND1 CDC73 CTNNB1 GNAS
9 immune system MP:0005387 10.42 APC BRAF CCND1 CDC73 CTNNB1 GNAS
10 mortality/aging MP:0010768 10.42 AIP APC BRAF CCND1 CDC73 CTNNB1
11 craniofacial MP:0005382 10.35 APC BRAF CCND1 CDC73 CTNNB1 GNAS
12 embryo MP:0005380 10.34 AIP APC BRAF CDC73 CTNNB1 KRAS
13 neoplasm MP:0002006 10.33 AIP APC BRAF CCND1 CDC73 CTNNB1
14 integument MP:0010771 10.31 AIP APC BRAF CCND1 CDC73 CTNNB1
15 nervous system MP:0003631 10.28 APC BRAF CCND1 CDC73 CTNNB1 GNAS
16 liver/biliary system MP:0005370 10.25 AIP APC BRAF CDC73 CTNNB1 GNAS
17 muscle MP:0005369 10.18 APC BRAF CDC73 CTNNB1 GNAS KRAS
18 limbs/digits/tail MP:0005371 10.13 APC BRAF CTNNB1 GNAS KRAS RET
19 hearing/vestibular/ear MP:0005377 10.12 APC BRAF CTNNB1 GNAS KRAS PLAG1
20 reproductive system MP:0005389 10.07 APC BRAF CCND1 CDC73 CTNNB1 KRAS
21 normal MP:0002873 10.06 APC BRAF CCND1 CTNNB1 GNAS KRAS
22 renal/urinary system MP:0005367 10.02 APC BRAF CDC73 CTNNB1 GNAS KRAS
23 respiratory system MP:0005388 9.85 BRAF CCND1 CDC73 CTNNB1 GNAS KRAS
24 pigmentation MP:0001186 9.77 APC BRAF CTNNB1 KRAS TGFBR2
25 skeleton MP:0005390 9.65 APC BRAF CCND1 CDC73 CTNNB1 GNAS
26 vision/eye MP:0005391 9.28 APC BRAF CCND1 CTNNB1 KRAS MLH1

Drugs & Therapeutics for Adenoma

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 453)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linaclotide Approved Phase 4 851199-59-2 65351
2
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
3
Metronidazole Approved Phase 4 443-48-1 4173
4
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
5
Dyclonine Approved Phase 4 586-60-7 3180
6
Pantoprazole Approved Phase 4 102625-70-7 4679
7
Clarithromycin Approved Phase 4 81103-11-9 84029
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
10
Prucalopride Approved Phase 4 179474-81-8
11
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
12
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
13
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
14
Bisacodyl Approved Phase 4 603-50-9
15
Methylene blue Approved, Investigational Phase 4 61-73-4
16
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
17
Glucagon Approved Phase 4 16941-32-5
18
Cinacalcet Approved Phase 4 226256-56-0 156419
19
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
20
Liraglutide Approved Phase 4 204656-20-2 44147092
21
Zinc Approved, Investigational Phase 4 7440-66-6 32051
22
Cefazolin Approved Phase 4 25953-19-9 656510 33255
23
Cefdinir Approved Phase 4 91832-40-5 6915944
24
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
25
Sulfamethoxazole Approved Phase 4 723-46-6 5329
26
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
27
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
28
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
29
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
30
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
31
Nitric Oxide Approved Phase 4 10102-43-9 145068
32
Pasireotide Approved Phase 4 396091-73-9 9941444
33
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
34
Cabergoline Approved Phase 4 81409-90-7 54746
35
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
36
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
37
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
38
Acetaminophen Approved Phase 4 103-90-2 1983
39
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
40
Codeine Approved, Illicit Phase 4 76-57-3 5284371
41
Sodium citrate Approved, Investigational Phase 4 68-04-2
42
Magnesium citrate Approved Phase 4 3344-18-1
43
lanreotide Approved Phase 4 108736-35-2
44
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
45
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
46
Ecabet Investigational Phase 4 33159-27-2, 86408-72-2 65781
47
Calcitonin gene-related peptide Investigational Phase 4 83652-28-2
48 Cholinergic Agents Phase 4
49 Muscarinic Antagonists Phase 4
50 Cholinergic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 1081)
# Name Status NCT ID Phase Drugs
1 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
2 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
3 Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. Unknown status NCT02175914 Phase 4 Erythromycin
4 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
5 Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial Unknown status NCT01767870 Phase 4
6 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Unknown status NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
7 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Unknown status NCT02832869 Phase 4
8 Comparison of the Efficacy and Tolerability Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Unknown status NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
9 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
10 Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
11 Efficacy of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial Unknown status NCT01308177 Phase 4 Ecabet
12 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
13 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
14 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
15 Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study Unknown status NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
16 Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy Unknown status NCT02781493 Phase 4 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen;2 mg Placebo plus 2 L Polyethylene Glycol regimen
17 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
18 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
19 Optimal Bowel Preparation Regimen for Patients With With a History of Colorectal Resection Before Colonoscopy Unknown status NCT02761317 Phase 4 standard preparation (2L PEG-ELS);low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS);high-volume preparation (4L PEG-ELS)
20 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
21 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
22 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
23 Comparative Efficacy of Water & Indigo Carmine vs Water or Air Method Completed NCT01607255 Phase 4 Indigo carmine
24 Prospective, Multicenter Study for the Evaluation of Safety and Performance of the Interscope EndoRotor Endoscopic Mucosal Resection System for the Removal of Alimentary Tract Mucosa in the Colon Completed NCT04203667 Phase 4
25 Can Involvement of Endoscopy Nurse Participation Increase Adenoma Detection Rate During Screening Colonoscopy?:A Prospective Multicenter Randomized Trial Completed NCT01124266 Phase 4
26 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
27 The Effect Of Adding High Dose Simethicone To A Standard Polyethylene Glycol Preparation On Adenoma Detection Rate During Screening Colonoscopy: A Randomized Controlled Pilot Trial Completed NCT03119168 Phase 4 Simethicone Solution
28 A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
29 A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
30 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
31 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy: A Prospective Randomized Study Completed NCT02507037 Phase 4 polyethylene glycol
32 Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial Completed NCT02078726 Phase 4 Glucagon;Placebo
33 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
34 Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas Completed NCT00521300 Phase 4 Octreotide
35 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
36 A Prospective Randomised Controlled Trial Comparing Cap-Assisted Colonoscopy Versus Standard Colonoscopy Completed NCT00930462 Phase 4
37 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
38 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
39 Tailored Bowel Preparation According to Bristol Stool Form Scale: a Prospective, Randomized, Controlled, Investigator-blinded, Multicenter Study Completed NCT02415569 Phase 4 Standard Bowel Prep (2L PEG-ELP);2L PEG-ELP and 10mg bisacodyl;Standard Bowel Prep (2L PEG-ELP)
40 Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH Completed NCT01494337 Phase 4
41 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
42 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
43 EFFICACY EVALUATION OF PRUNUS DOMESTICA EXTRACT ON BENIGN PROSTATE HYPERPLASIA (BPH): An Add on Study Completed NCT02702947 Phase 4
44 A Randomized, Double-blind, Comparative, Effectiveness and Safety Study of Eleview vs. Hetastarch in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 11mm Completed NCT03350217 Phase 4 Eleview;Hetastarch
45 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
46 Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan With Calcitonin Pre-treatment for Primary Hyperparathyroidism Recruiting NCT03935984 Phase 4 Calcitonin
47 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
48 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens Recruiting NCT03298945 Phase 4 Miralax-Gatorade Prep;Golytely
49 The Role of Aldosterone on Sympathetic Nerve Activity and Insulin Sensitivity Recruiting NCT02102243 Phase 4 DEFINITY® infusion;Human Recombinant Regular Insulin infusion;Dextrose infusion
50 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Active, not recruiting NCT02032784 Phase 4 octreotide

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Octreotide
Octreotide Acetate

Genetic Tests for Adenoma

Anatomical Context for Adenoma

MalaCards organs/tissues related to Adenoma:

40
Pituitary, Thyroid, Colon, Prostate, Salivary Gland, Liver, Testes

Publications for Adenoma

Articles related to Adenoma:

(show top 50) (show all 52933)
# Title Authors PMID Year
1
Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. 54 61
20514431 2010
2
Biallelic MYH germline mutations as cause of Muir-Torre syndrome. 61 54
19998059 2010
3
Immunohistochemical detection of somatostatin receptor subtype 5 (SSTR-5) in cushing adenoma. 54 61
19894022 2010
4
Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. 54 61
20196079 2010
5
Adrenocortical zonation in humans under normal and pathological conditions. 61 54
20200334 2010
6
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. 54 61
20107900 2010
7
AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas. 54 61
20503447 2010
8
The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. 61 54
20335450 2010
9
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. 54 61
20427397 2010
10
ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. 54 61
20307197 2010
11
KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. 61 54
20305537 2010
12
Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. 54 61
20060152 2010
13
Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients. 61 54
20332274 2010
14
REG IV overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study. 61 54
20183800 2010
15
Chemoprophylaxis in gastrointestinal tumors. 61 54
20496537 2010
16
Complete deletion of Apc results in severe polyposis in mice. 54 61
20010873 2010
17
Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. 61 54
20208994 2010
18
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. 54 61
20233436 2010
19
Identification of histologically distinct conventional adenomas that arise predominately in patients with sessile serrated adenomas. 54 61
20118768 2010
20
Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. 61 54
20111911 2010
21
Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. 54 61
20459557 2010
22
High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. 61 54
20145615 2010
23
Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. 54 61
19755524 2010
24
Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. 54 61
20086108 2010
25
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. 54 61
19965918 2010
26
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. 61 54
20087348 2010
27
O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report. 61 54
20087113 2010
28
Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. 61 54
20106827 2010
29
Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. 61 54
19855374 2010
30
The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. 61 54
20093774 2010
31
Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. 61 54
20145122 2010
32
ACTH-independent Cushing's syndrome with bilateral micronodular adrenal hyperplasia and ectopic adrenocortical adenoma. 54 61
19915020 2010
33
Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation. 61 54
20150876 2010
34
[Differentiated therapy of liver tumors]. 61 54
20062959 2010
35
Identifying mutations for MYH-associated polyposis. 61 54
20063264 2010
36
Gradual loss of functional gap junction within progression of colorectal cancer -- a shift from membranous CX32 and CX43 expression to cytoplasmic pattern during colorectal carcinogenesis. 61 54
20133984 2010
37
Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas. 54 61
19526345 2010
38
HERG1 gene expression as a specific tumor marker in colorectal tissues. 54 61
19577877 2010
39
Molecular genetics of hepatocellular neoplasia. 54 61
20182587 2010
40
Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. 61 54
19864471 2009
41
A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation. 61 54
19955943 2009
42
Clear cell change in colonic polyps. 54 61
18611940 2009
43
Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. 54 61
19745699 2009
44
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. 61 54
20046424 2009
45
Synaptophysin immunoreactivity in adrenocortical adenomas: a correlation between synaptophysin and CYP17A1 expression. 61 54
19755404 2009
46
An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1. 54 61
19253033 2009
47
[Effects of cyclooxygenase-2 and proliferating cell nuclear antigen on the onset and development of familial adenomatous polyposis]. 54 61
19895739 2009
48
Intestinal adenoma formation and MYC activation are regulated by cooperation between MYB and Wnt signaling. 61 54
19609274 2009
49
Expression of CD44 in canine mammary tumours. 54 61
19592009 2009
50
Colorectal mucosal expression of MSH2 as a potential biomarker of risk for colorectal neoplasms. 61 54
19861524 2009